Paul Keiser, MD
Allergy & Immunology · Rockville, MDNPI 1457476699
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 317 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by GSK at 26.6% of the total.
Across 317 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$583
- Novartis$466
- Sanofi$451
- Takeda Pharmaceuticals U.S.A., Inc.$407
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$1752%
- Food & beverage$6,87897%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 99 | $1,883 |
| AstraZeneca(2 entities) | 49 | $1,017 |
| Regeneron Healthcare Solutions, Inc. | 24 | $583 |
| Novartis | 26 | $466 |
| Sanofi | 18 | $451 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $407 |
| Aimmune Therapeutics, Inc. | 5 | $249 |
| Pfizer | 12 | $244 |
| Optinose US, Inc. | 9 | $183 |
| Kaleo, Inc. | 8 | $169 |
| Grifols USA, LLC | 8 | $169 |
| Genentech USA, Inc. | 7 | $161 |
| AbbVie | 2 | $148 |
| Alk-abello, Inc | 4 | $135 |
| Blueprint Medicines Corporation | 4 | $124 |
| Amgen(2 entities) | 5 | $113 |
| Galderma Laboratories, L.p. | 1 | $95 |
| Incyte Corporation | 4 | $84 |
| CSL Behring | 3 | $81 |
| Biocryst US Sales Co., LLC | 3 | $73 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Tersera Therapeutics LLC | 2 | $33 |
| Octapharma USA, Inc. | 1 | $30 |
| Aerin Medical Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $27 |
| USWM, LLC | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,092 in reported general payments places this provider in the 70th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 38 | $290,571 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 30 | $198,101 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $26,440 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $10,642 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,468 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,927 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,256 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $2,611 |
| Montelukast Sodium | 63 | $1,330 |
| Azelastine Hcl | 45 | $1,084 |
| Ipratropium Bromide | 33 | $1,048 |
| Desloratadine | 12 | $763 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $694 |
| Fluticasone Propionate | 35 | $521 |
| Levocetirizine Dihydrochloride | 16 | $513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga | $244 | $290,57138 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $407 | $198,10130 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,883 | $40,33854 claims |
| AstraZenecaSymbicort | $1,017 | $3,92715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 105 allergy & immunology providers in Maryland.
Other allergy & immunology in Rockville
- Sudhir SekhsariaRockville$87K
- Kristin SokolRockville$62K
- Rachel SchreiberRockville$48K
- Julia SohnRockville$16K
- Nneoma ObiejembaRockville$11K
- Jordana GoldmanRockville$6K
- Gina Dapul-HidalgoRockville$5K
- Ryan BolotteRockville$4K
- Antoine AzarBaltimore$612K
- Mark ScarupaWheaton$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.